TABLE 1

Hematopoietic cell chimerism posttransplantation

RecipientPreconditioning treatment (rad)GraftTransplanted cellsEngrafted mice/ transplanted miceDonor-derived PBMCs
CD3+ (%)B220+ (%)Mac-1+/Gr-1+ (%)
NOD (n = 16)950C57BL/6.H-2g7 HSC4,00016/1669.6 ± 8.096.9 ± 1.289.1 ± 16.7
NOD (n = 9)700C57BL/6.H-2g7 HSC4,0009/964.5 ± 5.690.6 ± 2.280.4 ± 12.1
NOD (n = 7)950C57BL/6.H-2g7 bone marrow6 × 1067/788.9 ± 3.398.9 ± 0.299.1 ± 0.6
NOD.SCID (n = 10)300C57BL/6.H-2g7 bone marrow6 × 1065/10*99.8 ± 0.199.7 ± 0.297.8 ± 3.4
  • Data are means ± SD. NOD or NOD.SCID mice were 8–9 weeks old at the time they were conditioned for AHCT with radiation treatment. Recipients received either C57BL/6.H-2g7 HSC or bone marrow grafts. Donor blood chimerism was evaluated at ∼50 days’ posttransplant by FACS analysis with double staining using CD45.2 and lineage-specific labeled monoclonal antibodies.

  • *

    * Five mice died before chimerism evaluation. PBMCs, peripheral blood mononuclear cells.